当前位置: 首页 > 期刊 > 《医药产业资讯》 > 2017年第11期
编号:13057644
血清中期因子、血小板因子4和黏蛋白1含量检测对乳腺癌患者病情评估的价值(4)
http://www.100md.com 2017年4月15日 《中国医药导报》 2017年第11期
     [10] Xu C,Zhu S,Wu M,et al. Functional receptors and intracellular signal pathways of midkine(MK)and pleiotrophin(PTN)[J]. Biol Pharm Bull,2014,37(4):511-520.

    [11] Li F,Tian P,Zhang J,et al. The clinical and prognostic significance of midkine in breast cancer patients [J]. Tumour Biol,2015,36(12):9789-9794.

    [12] 乔彩霞,王凤丽,孙霞霞,等.双抗间接夹心ELISA法检测乳腺癌患者外周血MUC1蛋白水平的评价[J].免疫学杂志,2012,28(5):436-439.

    [13] Cascio S,Finn OJ. Intra- and Extra-Cellular Events Related to Altered Glycosylation of MUC1 Promote Chronic Inflammation,Tumor Progression,Invasion,and Metastasis [J]. Biomolecules,2016,6(4):39-40.

    [14] Haddon L,Hugh J. MUC1-mediated motility in breast cancer:a review highlighting the role of the MUC1/ICAM-1/Src signaling triad [J]. Clin Exp Metastasis,2015,32(4):393-403.

    [15] Nicolini A,Ferrari P,Rossi G. Mucins and Cytokeratins as Serum Tumor Markers in Breast Cancer [J]. Adv Exp Med Biol,2015,867:197-225.

    [16] Fu Y,Li H. Assessing Clinical Significance of Serum CA15-3 and Carcinoembryonic Antigen(CEA)Levels in Breast Cancer Patients:A Meta-Analysis [J]. Med Sci Monit,2016, 22:3154-3162.

    (收稿日期:2016-11-17 本文編辑:张瑜杰), 百拇医药(郭志峰)
上一页1 2 3 4